Literature DB >> 28391371

Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Bobak Bahrami1,2, Thomas Hong1, Andrew Chang3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28391371     DOI： 10.1007/s00417-017-3670-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  7 in total

Review 1.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

Authors:  Bobak Bahrami; Meidong Zhu; Thomas Hong; Andrew Chang
Journal:  Diabetologia       Date:  2016-05-14       Impact factor: 10.122

2.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Bobak Bahrami; Thomas Hong; Meidong Zhu; Timothy E Schlub; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-25       Impact factor: 3.117

3.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

4.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Authors:  David M Brown; Quan Dong Nguyen; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Patricio G Schlottmann; Amy Chen Rundle; Jiameng Zhang; Roman G Rubio; Anthony P Adamis; Jason S Ehrlich; J Jill Hopkins
Journal:  Ophthalmology       Date:  2013-05-22       Impact factor: 12.079

5.  Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.

Authors:  Hamid Ahmadieh; Alireza Ramezani; Nasser Shoeibi; Bijan Bijanzadeh; Ali Tabatabaei; Mohsen Azarmina; Masoud Soheilian; Gholamreza Keshavarzi; Mohammad-Reza Mohebbi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-05       Impact factor: 3.117

6.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

7.  Intravitreal aflibercept for diabetic macular edema.

Authors:  Jean-François Korobelnik; Diana V Do; Ursula Schmidt-Erfurth; David S Boyer; Frank G Holz; Jeffrey S Heier; Edoardo Midena; Peter K Kaiser; Hiroko Terasaki; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; David M Brown
Journal:  Ophthalmology       Date:  2014-07-08       Impact factor: 12.079
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.